Prevenar 13 licensed from 5 years

The conjugate pneumococcal vaccine Prevenar 13 is now licensed for use in children aged 5-17 years.

Prevenar 13 was recently approved for the prevention of invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and over.
Prevenar 13 was recently approved for the prevention of invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and over.

Prevenar 13 is indicated for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae. The dose in children aged 5–17 years is 0.5ml by intramuscular injection, preferably into the deltoid muscle of the upper arm.

In an open-label study (n=592), a single dose of Prevenar 13 was given to children aged 5–10  years who had received at least one previous dose of Prevenar (7-valent) and to children aged 10–17 years who had never received a pneumococcal vaccine.

IgG response non-inferior to four-dose course in younger children

In all patients, the immune response to all 13 serotypes, as measured by serum IgG, was non-inferior to that observed in infants who received a four-dose course of Prevenar 13. In addition, functional antibody geometric mean titres one month following vaccination in children aged 10–17 years were non-inferior to those observed in the 5–10 year age group for 12 of the 13 serotypes (except serotype 3).

View Prevenar 13 drug record


Further information: Pfizer Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Prevenar 13 approved for pneumonia prevention in adults

Prevenar 13 approved for pneumonia prevention in adults

The pneumococcal vaccine Prevenar 13 can now be used...

News in brief - September 2013

News in brief - September 2013

Other new launches, licence changes and updates relevant...

Childhood vaccination schedule added to MIMS

Childhood vaccination schedule added to MIMS

A quick-reference guide to the current UK Childhood...

Prevenar 13 now indicated in adults

Prevenar 13 now indicated in adults

The licence for the pneumococcal conjugate vaccine...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more